Hi all, just something to read and ponder about any potential impacts to DXB-200 revenues/ profits if the below can be an alternative drug in reducing protein urea although from a different indication. I am not smart enough to understand it so posting it here so someone may educate me.
I am a believer in DXB.. not down ramping.
https://www.biopharmadive.com/news/apellis-drug-pegcetacoplan-success-kidney-disease-trial/723699/
Banter and general comments, page-22
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.0¢ |
Change
-0.005(1.20%) |
Mkt cap ! $228.3M | |||
| Open | High | Low | Value | Volume |
| 42.5¢ | 44.0¢ | 40.5¢ | $830.2K | 1.996M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 82165 | 41.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.5¢ | 164732 | 6 |
View Market Depth
| Last trade - 13.45pm 16/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |